HK Stock Market Move | LUYE PHARMA (02186) rose nearly 5%. New drug LY03020 approved for clinical trials in the United States.

LUYE PHARMA (02186) rose nearly 5%, reaching 4.98% as of the deadline, at HKD 2.11, with a trading volume of HKD 31.7741 million. On the news front, recently, LUYE PHARMA announced that the group's self-developed new generation antipsychotic drug LY03020 has obtained approval from the U.S. Food and Drug Administration to conduct clinical trials for the treatment of schizophrenia. LY03020 is based on the group's new molecular entity/new therapeutic entity technology platform, and is the world's first dual-target agonist of trace amine-associated receptor 1 and 5-hydroxytryptamine 2C receptor. LY03020 has also entered the clinical stage in China. According to the introduction, facing widespread unmet clinical needs, the new generation antipsychotic drugs are highly anticipated: different from the mechanism of already marketed antipsychotic drugs that inhibit post-synaptic membrane D2 and 5-HT2A receptors, this class of drugs is mainly characterized by stimulating pre-synaptic membranes, and is expected to reduce extrapyramidal symptoms and metabolic syndrome and significantly improve positive, negative, and cognitive symptoms of schizophrenia.